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Mortality beneﬁtsEditorial ‘‘Does modern medicine increase life-expectancy:
Quest for the Moon Rabbit?’’1 is very timely and really very
important given the hype created by the pharmaceutical industry
about drugs and devices highlighting their mortality beneﬁts.
Question is, what are the methods or parameters which tell us
about the mortality beneﬁts of a particular drug or intervention
and whether these can be inﬂuenced or not?2
1. Evidence-based medicine
Over the past 2 decades, evidence-based medicine (EBM) has
increasingly been accepted as the gold standard for decision-
making and standard for medical practice. Evidence-based practice
guidelines and EBM approaches are at the core of today’s scientiﬁc
thinking with RCTs being regarded as the fundamental research
response of EBM for healthcare.3 The beginnings of the EBM
approach were clearly focused on understanding the complexities
of the ‘workings of the healthcare system’ and its relationship to
making the ‘best possible decision’s for the care of patients’.
However, these complexities have rapidly been reduced to a narrow
focus on standardized and typically single disease management
guidelines.4,5 Epstein subscribing to the gold standard of RCTs,
mentioned the difﬁculty of using them as the main source of
information in outcome management/implementation and men-
tioned ‘prospective effectiveness trials’ as the alternative to RCTs.6
The reliance of EBM on the RCT is useful for acute (mostly single
disease) conditions treated with simple interventions, but this
approach is not suitable in the current epidemiological context
characterized by chronicity and multimorbidity in complex health
systems. In particular, EBM has largely disregarded the importance
of social determinants of health and local context and its real impact
on the ‘effectiveness’ and ‘efﬁciency’ of healthcare on the ‘equality’
of needed healthcare services.7,8
2. Can EBM be inﬂuenced?
Doubts have been raised by large number of health profes-
sionals that pharmaceutical companies have inﬁltrated the
medical research institutions and inﬂuenced peer-review process
to promote drug marketing and a few but inﬂuential medical critics
believe that the validity and veracity of peer-reviewed research is0019-4832/ 2016 Published by Elsevier B.V. on behalf of Cardiological Society of
creativecommons.org/licenses/by-nc-nd/4.0/).being undermined, subverting the foundation of EBM.2,9 Research-
ers believe that unfavorable research results are eliminated from or
camouﬂaged in the texts of industry-inﬂuenced studies and that
data often are remolded in ways that present favorable results
when a more transparent analysis might reveal substantial risk
for patients taking the ‘‘hyped’’ medications.10 Internist John
Abramson,11 wrote that the pharmaceutical industry has inserted
itself into every aspect of medical practice from medical education
to basic research and clinical care, enticing a number of respectable
research physicians into endorsing questionable studies, co-opting
the mechanisms of evaluation of effective treatment for widely
accepted illnesses, but also it has successfully colonized the
healthy population by the construction of an array of new
illnesses.12 Despite the idealized claim that EBM would be the
product of objective research conducted by disinterested medical
researchers, pharmaceutical industry-sponsored clinical trials can
have a corrosive impact both on physicians who derive substantial
income from their participation and, in turn, on evidence claims
themselves. Moreover, not all clinical trial results are published,
especially those whose results fail to demonstrate the beneﬁts of
an agent in a pharmaceutical-sponsored trial.13 Because of
increasing concerns of EBM being inﬂuenced, a special communi-
cation published in January 2006 in JAMA by a consortium of
distinguished researchers, practitioners, and ethicists urged
adoption of a series of measures aimed at insulating practitioners
and academic medical researchers from what they believed to be
the pharmaceutical industry’s corrosive effect on medical research
and practice.14 These recommendations reveal the growing
anxiety, among some highly regarded and inﬂuential medical
faculty, that the pharmaceutical industry has placed the practice of
medicine, especially EBM, at dire risk.
3. Medical research and funding
Since 1980, the share of biomedical research funding from
industry sources has grown from 32% to 62%.15 In USA, industry-
sponsored research accounts for 58% of expenditures, NIH for 27%
of expenditures, state governments for 5% of expenditures, non-
NIH-federal sources for 5% of expenditures, and not-for-proﬁt
entities accounted for 4% of support.16 The relationship that exists
with industry-funded biomedical research is that of which
industry is the ﬁnancier for academic institutions which in turn
employ scientiﬁc investigators to conduct research. A fear exists
that a project funded by industry might hide negative effects to
promote their product.17
4. Medical research and pharmaceutical industry
Three recent systematic reviews have shown that pharmaceuti-
cal industry funding of clinical trials is strongly associated with pro-
industry results. There are multiple demonstrated causes of the India. This is an open access article under the CC BY-NC-ND license (http://
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publication bias; these are all rooted in close contact between
pharmaceutical companies and clinical research.18 To practice, EBM
physicians need data on the clinical effectiveness, toxicity,
convenience, and cost of new drugs compared with available
alternatives and an article highlighted examples of published drug
studies that are defective, sometimes because pharmaceutical
industry funding has affected their content and quality.19 There was
a statistically signiﬁcant association between the sources of funding
and the outcome of the study. Three hypotheses were considered to
explain these results: industry selects drugs likely to prove
efﬁcacious, study results are ﬂawed because of sample not large
enough, and researchers fear discontinuation of funding if studies
do not show favorable results.20 Results of several studies suggest
that the source of funding affects decision-making by recipients.
Research support from pharmaceutical companies was an inde-
pendent predictor of requests for formulary additions from internal
medicine faculty members at seven Midwest US teaching
hospitals.21 Another study reported a bias in favor of the sponsoring
company’s drug.22 Another study showed a greater increase in
prescriptions for the drug made by the sponsoring company than
for other drugs in the same class.23
5. Is there a conspiracy preventing a disease cure?
There are people like me who believe that research on disease
cure will never get funding and promotion because pharmaceu-
ticals have a vested interest in keeping disease around as long as
possible because treating disease is simply far too proﬁtable than a
cure could ever be. Take the example of diabetes, which is a multi-
billion dollar industry, including sales of insulin, new and old oral
agents and medical devices such as insulin pumps, glucose
monitors and their pricey test strips, and new continuous glucose
monitors. Why any pharma company will fund a cure for diabetes
and kill a goose with golden eggs. John Thomas in an article explains
why the current cancer industry prospers while treating cancer, but
cannot afford to cure it.24 An article reported that in 2010, Gleevec
grossed $4.3 billion. Roche’s Herceptin (the HER2 drug) and Avastin
did even better: $6 billion and $7.4 billion respectively. Cancer plays
a huge role in the rising costs of healthcare. America’s National
Institutes of Health predict that spending on all cancer treatment
will rise from $125 billion last year to at least $158 billion in 2020.25
The cancer factory is truly big business in America. This system
cannot afford to permit anyone to ﬁnd a cure for cancer. If any of the
low cost highly successful alternative cancer treatments were to be
approved for use, then this entire system would come crashing
down. The pharmaceutical cartel will not let that happen.26
6. Conclusion
Beneﬁts of therapeutic interventions (drugs and devices) are
measured by various trials, what is known as EBM and fears are
expressed that it can be inﬂuenced. Hype is created in favor of
mortality beneﬁts of drugs and devices, neglecting the immense
morbidity and mortality beneﬁts of life style modiﬁcations, which
remain the most useful strategy for prolonging life at any stage,
primary, secondary, or tertiary prevention. Moreover, drugs and
devices are expensive and have some side effects, where as a
healthy lifestyle is inexpensive, safe, and effective. Interventions or
drug treatment of acute single disease deﬁnitely scores over life
style modiﬁcations, but for all other stages of diseases, life style
modiﬁcations are the best for mortality beneﬁts. Such a scenario
leaves common physician confused which trial to believe and
follow. I ﬁrmly believe that under the hypnotizing inﬂuence of
commercialization and market forces, common physician are
reduced to a miserable pawn in the larger game of disease and fear.Conﬂicts of interest
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